

****Published May 2017****

MarketVIEW: Rhinovirus vaccines (CAT: VAMV066)

Product Name	:	MarketVIEW: Rhinovirus vaccines
Description	:	Vaccine opportunity assessment
Contents	:	Executive presentation (.pdf) + forecast model (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	May 2017
Catalogue No	:	VAMV066

Background

Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.

A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development but preclinical activity is ongoing.

The **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. **LO/BASE/Hi** forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Rhinovirus spp, respiratory viruses, and related indications e.g. asthma and COPD. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel viral vaccines has also been utilised.

PRODUCT CONTENTS:

Published May 2017 (CAT No: VAMV066)

****This product is composed of **one** forecast model (.xls)¹ and a summary presentation (.pdf)²

Title page
Contents
Author's note
Executive summary
HRV vaccines commercial model: key outputs
HRV vaccines: potential value (\$m) by low/base/high price to 2030
HRV vaccines: potential value (\$m) by target population (base price) to 2030
HRV vaccines: potential value (\$m) by region (base price) to 2030
HRV: background and epidemiology
Human rhinovirus: overview
HRV – genotypes
HRV - transmission, pathogenesis and host response¹
Epidemiology: HRV disease burden
Epidemiology: data – England 2009-2012
Disease burden caused by common respiratory viruses
HRV disease burden: adults
HRV disease burden: respiratory viral infections and hospitalization
HRV disease burden: adults - summary
HRV disease burden: infants
Human rhinovirus: risk factors for severe infant infection
HRV disease burden: infants - summary
HRV disease burden: elderly
HRV disease burden: elderly – comparative to other viruses
HRV - mortality of hospitalised elderly patients versus flu
HRV disease burden: elderly – COPD
HRV disease burden: elderly – risk groups
HRV disease burden: asthma exacerbations
HRV disease burden: asthma exacerbations – association
HRV disease burden: asthma exacerbations – therapies
HRV disease burden: asthma exacerbations & HRV vaccine
HRV disease burden: asthma exacerbations – unmet need
HRV - a cause of childhood asthma?
HRV disease burden: COPD exacerbations
HRV disease burden: COPD exacerbations & viral infection
HRV disease burden: COPD exacerbations & disease severity
HRV disease burden: COPD exacerbations & related costs
HRV disease burden: COPD exacerbations & treatments

¹ Model contents available upon application

² Presentation titles may apply to more than one slide

Continued.....

HRV disease burden: COPD exacerbations & economics
HRV disease burden: COPD exacerbations & HRV vaccine
HRV - other risk groups (HSCTs)
HRV vaccines – R&D pipeline
ViravaxX - HRV vaccine
A putative HRV vaccine: commercial model assumptions
The role of an HRV vaccine
HRV vaccine target product profile (TPP)
HRV vaccine: points to note
Main target markets for HRV vaccines
Commercial model: major inputs
Drivers and resisters for a successful HRV vaccine
Commercial parameters of respiratory viruses vaccines
Back-up: methodology
Methodology: populations (COPD)
Methodology: populations – COPD per country
Methodology: populations – asthma
Methodology: populations – asthma prevalence
Methodology: vaccine uptake
About **VacZine Analytics**
Disclaimer

Slide number = 77

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$10,995.00**/ GBP **£8795.00**[#] (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Jacobs SE et al. Human Rhinoviruses. *Clin Micro Reviews*. 2013 vol 26 no 1 135-162
2. Arruda E et al. Frequency and natural history of rhinovirus infections in adults during autumn. *J Clin Microbiol*. 1997 Nov;35(11):2864-8
3. Khetsuriani, N. et al. Novel human rhinoviruses and exacerbation of asthma in children. *Emerg Infect Dis* 14, 1793–1796 (2008)
4. Miller, E. K. et al. Human rhinovirus C associated with wheezing in hospitalised children in the Middle East. *J Clin Virol* 46, 85–89 (2009)
5. Cuevas MT et al. Spread of different rhinovirus B genotypes in hospitalized children in Spain. *Influenza J*. Vol 7, Issue 5, 6 DEC 2012
6. Aponte F et al. Rhinovirus is an important pathogen in upper and lower respiratory tract infections in Mexican children. *Virology J* 2015 12:31
7. Xiang Z et al. Human Rhinovirus C infections mirror those of human rhinovirus A in children with community-acquired pneumonia. *J Clin Virology*. Vol 49, Issue 2 pages 94-99
8. Fendrick AM, Monto AS, Nightengale B, Sarnes M. 2003. The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch. Intern. Med.* 163:487–494
9. Tanner HE. Viral respiratory infections during the 2009 influenza A(H1N1) outbreak in the West Midlands Region, UK. *Epidemiol Infect.* 2012 Sep;140(9):1551-6.
10. Jartti T et al. Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. 2008 *Ped Inf Dis J* 27:1103-1107
11. Zhao H et al. A new laboratory-based surveillance system (Respiratory DataMart System) for influenza and other respiratory viruses in England: results and experience from 2009 to 2012. *Euro Surveill*. 2014 Jan 23;19(3). pii: 20680
12. Miller EK et al. Hospitalizations and outpatient visits for rhinovirus-associated acute respiratory illness in adults. *J Allergy Clin Immunol*. 2015 Aug 6.
13. CDC. Seasonal Influenza-Associated Hospitalizations in the United States. Available at: <http://www.cdc.gov/flu/about/qa/hospital.htm>
14. Falsey AR et al. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med*. 2005 Apr 28;352(17):1749-59.
15. Widmer K et al. Respiratory syncytial virus and human metapneumovirus emergency department and hospital burden in adults. *Influenza Other Respir Viruses*. 2014 May;8(3):347-52.
16. Thompson WW et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA*. 2003 Jan 8;289(2):179-86
17. Walker E, Ison MG. Respiratory viral infections among hospitalized adults: experience of a single tertiary healthcare hospital. *Influenza Other Respir Viruses*. 2014 May;8(3):282-92.
18. Bender JM et al. Infants 1-90 days old hospitalized with human rhinovirus infection. *J Clin Lab Anal*. 2014 Sep;28(5):349-52
19. Marguet C et al. In very young infants severity of acute bronchiolitis depends on carried viruses. *PLoS One*. 2009;4(2):e4596
20. Costa LF et al. Human rhinovirus and disease severity in children. *Pediatrics*. 2014 Feb;133(2):e312-21
21. Jartti T et al. Hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis. *Pediatr Infect Dis J*. 2014 Aug;33(8):829-34
22. Miller K et al. Host factors and viral factors associated with severity of human rhinovirus infant respiratory illness. *J Allergy Clin Immunol* Apr 127 (4): 883-891
23. Falsey AR et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. *J Infect Dis*. 2014 Jun 15;209(12):1873-81
24. Hung I et al. Unexpectedly Higher Morbidity and Mortality of Hospitalized Elderly Patients Associated with Rhinovirus Compared with Influenza Virus Respiratory Tract Infection. *Int. J. Mol. Sci*. 2017, 18(2), 259
25. Pierangeli A et al Rhinovirus frequently detected in elderly adults attending an emergency department. *J Med Virol*. 2011 Nov;83(11):2043-7.
26. CDC. Asthma FastStats. Available at: <http://www.cdc.gov/nchs/faststats/asthma.htm>. Accessed May 2017
27. Schatz M et al. (2014). Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy. *J Allergy Clin Immunol Pract.*; 2(5):570-4.e1
28. Hermosa JL et al. (2010). Factors associated with the control of severe asthma. *J Asthma*; 47(2):124-30
29. Dougherty RH et al. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. *Clin Exp Allergy*. 2009 Feb;39(2):193-202
30. Olenec JP et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. *J Allergy Clin Immunol*. 2010 May;125(5):1001-1006.e1
31. Corne JM et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. *Lancet*. 2002 Mar 9;359(9309):831-4
32. Johnston NW, Sears MR. Asthma exacerbations: epidemiology. *Thorax*. 2006 Aug;61(8):722-8.
33. Johnston NW. et al. The September epidemic of asthma exacerbations in children: a search for etiology. *J Allergy Clin Immunol* 2005;112:132–8
34. Johnston SL, G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ* 1995;310:1225–9

35. Nicholson KG et al. Respiratory viruses and exacerbations of asthma in adults. *BMJ*. 1993 Oct 16;307(6910):982-6.
36. Grissell TV et al. Interleukin-10 gene expression in acute virus-induced asthma. *Am J Respir Crit Care Med*. 2005 Aug 15;172(4):433-9.
37. Humbert M et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy*. 2005 Mar;60(3):309-16.
38. Burton AJ et al. The Eligibility Of Patients With Difficult Asthma For Omalizumab Since The Change To The Treatment Criteria. *Thorax*; 65: A84-A85.
39. Ortega HG et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. 2014 Sep 25;371(13):1198-207.
40. Newby C. et al. (2014). Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. *PLoS One*.24;9(7):e102987.
41. Chung KF et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014 Feb;43(2):343-73.
42. Thomson NC, Chaudhuri R. Identification and management of adults with asthma prone to exacerbations: can we do better? *BMC Pulm Med*. 2008 Dec 30;8:27.
43. Stone CA et al. Understanding the Association of Human Rhinovirus with Asthma. *Clin Vaccine Immunol*. Jan 2016 vol 23 no 1, 6-10
44. Jackson D et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Crit Care Med* 178:667-672
45. Nagarkar D et al. 2010. Rhinovirus infection of allergen-sensitized and-challenged mice induces eotaxin release from functionally polarized macrophages. *J Immunol* 185:2525–2535. doi:10.4049/jimmunol.1000286
46. Mallia P et al. 2011. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. *Am J Respir Crit Care Med* 183:734–742. doi:10.1164/rccm.201006-0833OC
47. HCUPnet. Agency for Healthcare Research and Quality. Available at: <http://hcupnet.ahrq.gov/>. Accessed: January 2016
48. Løkke A. et al. (2014) Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. *BMJ Open*.;4(1):e004069.
49. Welte T, Miravittles M. Viral, bacterial or both? Regardless, we need to treat infection in COPD. *Eur Respir J*. 2014 Jul;44(1):11-3.
50. Beasley V. et al. Lung microbiology and exacerbations in COPD. *Int J Chron Obstruct Pulmon Dis*. 2012;7:555-69
51. Kurai D et al. Virus-induced exacerbations in asthma and COPD. *Front Microbiol*. 2013 Oct 1;4:293.
52. Koul PA et al. Respiratory viruses in acute exacerbations of COPD. *Lung India*. 2017. Vol 34: 29-33
53. Hurst JR et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010 Sep 16;363(12):1128-38
54. Dhamane AD et al. COPD exacerbation frequency and its association with health care resource utilization and costs. *Int J Chron Obstruct Pulmon Dis*. 2015 Dec 3;10:2609-18.
55. Najafzadeh M. et al. (2012). Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. *PLoS One*. 7(10):e46746.
56. George SN et al. Human rhinovirus infection during naturally occurring COPD exacerbations. *Eur Respir J*. 2014 Jul;44(1):87-96.
57. Englelmann I et al. In Vivo Persistence of Human Rhinoviruses in Immunosuppressed Patients. *PLoS ONE* 12(2): e0170774.
58. Seo S et al. Human Rhinovirus Detection In The Lower Respiratory Tract Of Hematopoietic Cell Transplant Recipients: Association With Mortality. *Haematologica* February 2017 : haematol.2016.153767
59. Glanville N, Johnston SL. Challenges in developing a cross-serotype rhinovirus vaccine. *Curr Opin Virol*. 2015 Apr;11:83-8.
60. McLean GR .Developing a vaccine for human rhinoviruses. *J Vaccines Immun*. 2014 Oct 1;2(3):16-20.
61. Ren L et al. Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21. *Scientific Reports* 7, Article number: 41601 (2017)
62. Lee SL et al. A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. *Nat communications* 7, 12838 (2016)
63. Gabarron P et al. Recombinant baculovirus vector development for universal vaccine production against human cold virus *Biosaia Inicio Num* 6 (2017)
64. ViravaxX Corporate Website. Available at: <http://www.viravaxx.eu/>. Accessed April 2017
65. Edlmayr J, Niespodziana K, Popow-Kraupp T, Krzyzaneck V, Focke-Tejkl M, Blaas D, Grote M, Valenta R. (2011) Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. *Eur Respir J*. 37(1):44-52
66. UK Independent News Article. January 2017. Available at: <http://www.independent.co.uk/life-style/health-and-families/health-news/common-cold-vaccine-patent-body-fights-disease-wrong-way-rudolf-valenta-vienna-university-a7519171.html>. Accessed April 2017
67. Glanville N. et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. *PLoS Pathog*. 2013; 9:e1003669
68. Garrastazu R et al. Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. *Arch Bronconeumol*. 2015 Oct 29
69. VacZine Analytics. MarketVIEW. Respiratory syncytial virus vaccines. CAT No: VAMV023, updated April 2014
70. VacZine Analytics. MarketVIEW. Human Metapneumovirus vaccines. CAT No: VAMV062, published June 2015
71. Bednarek M et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. *Thorax*. 2008 May;63(5):402-7.
72. Raluy-Callado M. et al. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. *Int J Chron Obstruct Pulmon Dis*. 2015 May 13;10:925-37.

73. von Bülow A, Kriegbaum M, Backer V, et al. (2014). The prevalence of severe asthma and low asthma control among Danish adults. *J Allergy Clin Immunol Pract.*;2(6):759-67.
74. Centers for Disease Control and Prevention (CDC). Vaccination coverage among persons with asthma -- United States, 2010-2011 influenza season. *MMWR Morb Mortal Wkly Rep.* 2013 Dec 6;62(48):973-8.
75. Asciak R et al. Predictors of seasonal influenza vaccination in chronic asthma. *Multidiscip Respir Med.* 2013 Oct 21;8(1):68.
76. Garrastazu R et al. Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. *Arch Bronconeumol.* 2015 Oct 29. pii: S0300-2896(15)00354-3.
77. Chiatti C et al. Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: a secondary analysis of the multipurpose ISTAT survey on health and health care use. *Hum Vaccin.* 2011 Oct;7(10):1021-5.
78. Schembri S et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. *Thorax.* 2009 Jul;64(7):567-72.



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009